Selected Publications

ZIKA Vaccine 

Larocca RAAbbink PPeron JPZanotto PMIampietro MJBadamchi-Zadeh ABoyd MNg'ang'a DKirilova MNityanandam RMercado NBLi ZMoseley ETBricault CABorducchi ENGiglio PBJetton DNeubauer GNkolola JPMaxfield LFBarrera RAJarman RG3Eckels KH,Michael NLThomas SJBarouch DHVaccine protection against Zika virus from Brazil. Nature 2016

    Abbink PLarocca RADe La Barrera RABricault CAMoseley ET, Boyd M Kirilova M Li Z Ng'ang'a D Nanayakkara O Nityanandam R,Mercado NBBorducchi ENAgarwal ABrinkman ALCabral CChandrashekar AGiglio PBJetton DJimenez JLee BCMojta SMolloy K,Shetty MNeubauer GHStephenson KE Peron JP Zanotto PM Misamore J Finneyfrock B Lewis MG Alter G Modjarrad K Jarman RG Eckels KH Michael NL Thomas SJ Barouch DHProtective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 2016

    Development of Novel HIV- Vaccine Vectors and Immunogens

    Roberts DR, Nanda A, Havenga MJE, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AAC, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.  Hexon chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.  Nature 2006; 441:239-243.

    Barouch DH.  Challenges in the development of an HIV-1 vaccine.  Nature 2008; 455:613-619.  PMC2572109.

    O’Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH.  Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.  Nat. Med. 2009; 15:873-875.  PMC2756115.

    Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B.  Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.  Nat. Med. 2010; 16:319-323.  PMC2834868.

    Immune Correlates of Protection in Rhesus Monkeys

    Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, CE, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.  Science 2000; 290:486-492.

    Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH.  Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.  Nature 2009; 457:87-91.  PMC2614452.

    Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EM, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.  Nature 2012; 482:89-93.  PMC3271177.

    Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL.  Protective efficacy of a global HIV-1 mosaic vaccine against acquisition of heterologous SHIV challenges in rhesus monkeys.  Cell 2013; 155:531-539.  PMC3846288.

     

    Viral Pathogenesis

    Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.  Nature 2002; 415:335-339.

    Barouch DH, Powers J, Truitt DM, Kishko MG, Arthur JC, Peyerl FW, Kuroda MJ, Gorgone DA, Lifton MA, Lord CI, Hirsch VM, Montefiori DC, Carville A, Mansfield KG, Kunstman KJ, Wolinsky SM, Letvin NL.  Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants.  Nat. Immunol. 2005; 6:247-252.

    Handley S, Thackray LB, Zhao G, Presti R, Miller A, Droit L, Abbink P, Maxfield LF, Kambal A, Duan E, Stanley K, Kramer J, Macri SC, Permar SR, Schmitz JE, Mansfield K, Brenchley J, Veazey RS, Stappenbeck TS, Wang D, Barouch DH*, Virgin HW*.  Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome.  Cell 2012; 151:253-266.  PMC3490196.

    Penaloza-MacMaster P, Barber DL, Wherry EJ, Provine NM, Teigler JE, Parenteau L, Blackmore S, Borducchi EN, Larocca RA, Yates K, Shen H, Haining WN, Sommerstein R, Pinschewer DD, Ahmed R, Barouch DH.  Immunopathology of vaccine-elicited CD4 T cells following chronic LCMV infection.  Science 2015; in press.

     

    Clinical HIV-1 Vaccine Development

    Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH.  First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).  J. Infect. Dis. 2013; 207:240-247.  PMC3532831.

    Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR.  Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).  J. Infect. Dis. 2013; 207:248-256.  PMC3532832.

    Barouch DH.  The quest for an HIV vaccine – moving forward.  New Engl. J. Med. 2013; 369:2073-2076.  PMC4239025.

    Barouch DH, Michael NL.  Accelerating HIV-1 vaccine efficacy trials.  Cell 2014; 159:969-972.

     

    Establishment and Targeting of the Viral Reservoir

    Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.  Nature 2013; 503:224-228.  PMC4017780.

    Barouch DH, Deeks SG.  Immunologic strategies for HIV-1 remission and eradication.  Science 2014; 345:169-174.  PMC4096716.

    Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DIS, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH.  Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.  Nature 2014; 512:74-77.  PMC4126858.